The lull is over. The annual February pause in IPO activity lasted longer than normal, but 2018's record-breaking start now looks ready to resume. This week IPOs began launching and another billion-dollar IPO joined ...read more
BioXcel Therapeutics, which is developing new uses of drugs to treat neurological disorders and cancer, raised $60 million by offering 5.5 million shares at $11, the low end of the range of $11 to $13. BioXcel Therapeutics plans to list on the Nasdaq under the...read more
Only one small biotech is on the calendar for the week ahead as the annual mid-February lull has been drawn out slightly longer than expected. That said, four deals are able to launch on Monday and another three become eligible the week after, including...read more
BioXcel Therapeutics, which is utilizing AI to develop new uses of drugs to treat neurological disorders and cancer, announced terms for its IPO on Tuesday. The Branford, CT-based company plans to raise $60 million by offering 5.0 million shares at a price...read more
US IPO Weekly Recap: Another billion-dollar IPO filing as activity prepares to pick up
The lull is over. The annual February pause in IPO activity lasted longer than normal, but 2018's record-breaking start now looks ready to resume. This week IPOs began launching and another billion-dollar IPO joined ...read more
BioXcel Therapeutics prices IPO at $11, the low end of the range
BioXcel Therapeutics, which is developing new uses of drugs to treat neurological disorders and cancer, raised $60 million by offering 5.5 million shares at $11, the low end of the range of $11 to $13. BioXcel Therapeutics plans to list on the Nasdaq under the...read more
US IPO Week Ahead: 1 biotech expected in the week ahead, 4 deals could launch starting Monday
Only one small biotech is on the calendar for the week ahead as the annual mid-February lull has been drawn out slightly longer than expected. That said, four deals are able to launch on Monday and another three become eligible the week after, including...read more
AI-based drug discovery biotech BioXcel Therapeutics sets terms for $60 million IPO
BioXcel Therapeutics, which is utilizing AI to develop new uses of drugs to treat neurological disorders and cancer, announced terms for its IPO on Tuesday. The Branford, CT-based company plans to raise $60 million by offering 5.0 million shares at a price...read more